PACB: Pacific Biosciences of California, Inc.
About
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Current Value
$2.381 Year Return
Current Value
$2.381 Year Return
Key Details
Market Cap
$640.84M
P/E Ratio
-1.61
1Y Stock Return
-71.84%
1Y Revenue Growth
2.14%
Dividend Yield
0.00%
Price to Book
1.4
Strategies that include PACB
Stock's related to PACB
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TXG | 54.40% | $1.96B | -66.80% | 0.00% |
| AZTA | 50.24% | $2.11B | -20.89% | 0.00% |
| ABCL | 48.82% | $892.01M | -36.82% | 0.00% |
| ADPT | 48.33% | $990.26M | +53.20% | 0.00% |
| GRAL | 48.11% | $688.98M | +20.62% | 0.00% |
| ILMN | 46.98% | $23.56B | +29.59% | 0.00% |
| TDOC | 46.59% | $1.82B | -44.50% | 0.00% |
| SDGR | 46.28% | $1.61B | -29.74% | 0.00% |
| RVTY | 45.41% | $14.34B | +31.72% | 0.24% |
| NTLA | 45.33% | $1.50B | -47.71% | 0.00% |
| CRSP | 44.84% | $4.16B | -16.24% | 0.00% |
| DDD | 44.38% | $447.55M | -43.20% | 0.00% |
| CRSR | 43.91% | $833.41M | -43.59% | 0.00% |
| CLFD | 43.89% | $464.24M | +16.20% | 0.00% |
| CPS | 43.46% | $268.39M | -4.85% | 0.00% |
| GBIO | 43.23% | $85.49M | -28.89% | 0.00% |
| HBT | 43.16% | $754.59M | +20.27% | 3.14% |
| PKST | 43.13% | $465.69M | -27.40% | 6.99% |
| TWST | 43.09% | $3.06B | +82.51% | 0.00% |
| EDIT | 43.09% | $173.35M | -78.66% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LPTH | -0.03% | $75.36M | +37.68% | 0.00% |
| LLY | 0.04% | $759.05B | +36.74% | 0.65% |
| MRK | -0.18% | $255.49B | -3.22% | 3.06% |
| KMB | -0.21% | $44.38B | +9.28% | 3.66% |
| FTNT | 0.35% | $74.45B | +76.47% | 0.00% |
| SE | 0.50% | $59.25B | +190.59% | 0.00% |
| NFLX | -0.62% | $390.42B | +97.27% | 0.00% |
| KHC | 0.66% | $38.20B | -15.22% | 5.05% |
| CYD | -0.68% | $370.18M | +10.76% | 4.19% |
| CLX | 0.75% | $20.75B | +17.79% | 2.87% |
| UNH | -0.79% | $520.14B | +3.57% | 1.47% |
| XOS | 0.81% | $29.79M | -35.14% | 0.00% |
| GAN | 0.84% | $84.30M | +14.20% | 0.00% |
| NEUE | 0.86% | $43.41M | -19.51% | 0.00% |
| CYCN | -0.87% | $11.30M | +58.56% | 0.00% |
| XBIO | -0.89% | $6.71M | +18.85% | 0.00% |
| NERV | -0.90% | $16.36M | -63.15% | 0.00% |
| OXBR | -0.92% | $22.54M | +251.46% | 0.00% |
| CCEC | -0.93% | $1.01B | +39.16% | 3.28% |
| AVAV | 0.93% | $4.34B | +22.85% | 0.00% |
ETF's related to PACB
News
Finnhub
Item 1.01 Entry Into a Material Definitive Agreement. On November 21, 2024, Pacific Biosciences of California, Inc. consummated the previously announced privately negotiated...
Yahoo
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in […]
Yahoo
The rock star money manager is starting to roll with the rallying market.
SeekingAlpha
Pacific Biosciences of California stock surged 50% despite a revenue decline & low margins. See why I think maintaining a sell recommendation on PACB is prudent.
Yahoo
Pacific Biosciences of California ( NASDAQ:PACB ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.0m...
Yahoo
Last week, you might have seen that Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) released its third-quarter...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.